Modified twist drill technique in the management of chronic subdural hematoma

Turkish Neurosurgery

Volumn 23, Issue 1, 2013, Pages 55-60

  Zuhur, Sayid Shafi ^a   Tanik, Canan ^a   Erol, Rumeysa Selvinaz ^a   Musluman, Ahmet Murat ^a   Kabukcuoglu, Fevziye ^a   Altuntas, Yuksel ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adamantinomatous craniopharyngioma; EGFR; ErbB2; Immunohistochemistry; Catenin

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CHILD; CRANIOPHARYNGIOMA; FEMALE; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BETA CATENIN; CELL DIFFERENTIATION; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; CRANIOPHARYNGIOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTOR, ERBB-2; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874928725     PISSN: 10195149     EISSN: None     Source Type: Journal    
DOI: 10.5137/1019-5149.JTN.6706-12.1     Document Type: Article

References (32)

1. Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Le Tissier P, Jacques TS, Pevny LH, Dattani MT, Martinez-Barbera JP: Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol doi: 10.1007/s00401- 012-0957-9
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9(1):16-32, 2011
3. Blackwell KL, Burstein HJ, Storniolo AM, Rugo, H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28: 1124-1130, 2010
4. Botelho CH, Magalhaes AV, Mello PA, Schmitt FC, Casulari LA: Expression of p53, Ki-67 and cerbB2 in growth hormone-and/ or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 64: 60-66, 2006
5. Buslei R, Hölsken A, Hofmann B, Kreutzer J, Siebzehnrubl F, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Blümcke I: Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol 113(5):585-590, 2007
6. Camper SA: Beta-catenin stimulates pituitary stem cells to form aggressive tumors. Proc Natl Acad Sci U S A. 108(28):11303-11304, 2011
7. Cani CM, Matushita H, Carvalho LR, Soares IC, Brito LP, Almeida MQ, Mendonça BB: PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations. Clinics (Sao Paulo) 66(11):1849-1854, 2011
8. Cao J, Lin JP, Yang LX, Chen K, Huang ZS: Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas. Br J Neurosurg 24(3):249-256, 2010
9. Cooper O, Vlotides G, Fukuoka H, Greene MI, Melmed S: Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer 18: R197-R211, 2011
10. Edgar MA, Rosenblum MK: The differential diagnosis of central nervous system tumors: A critical examination of some recent immunohistochemical applications. Arch Pathol Lab Med 132(3):500-509, 2008
11. Elsahwi KS, Santin AD: erbB2 Overexpression in Uterine Serous Cancer: A molecular target for trastuzumab therapy. Obstet Gynecol Int 2011:128295, 2011
12. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S, Melmed S: HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: Strategy for targeted prolactinoma therapy. Mol Endocrinol 25: 92-103, 2011
13. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S: EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121(12):4712-4721, 2011
14. Garnett MR, Puget S, Grill J, Sainte-Rose C: Craniopharyngioma. Orphanet J Rare Dis 2:18, 2007
15. Gao S, Shi X, Wang Y, Qian H, Liu C: Malignant transformation of craniopharyngioma: Case report and review of the literature. J Neurooncol 103: 719-725, 2011
16. Hölsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: EGFR Signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 2 17:4367-4377, 2011
17. Hölsken A, Buchfelder M, Fahlbusch R, Blumcke I, Buslei R: Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling. Acta Neuropathol 119:631-639, 2010
18. Hölsken A, Kreutzer J, Hofmann BM, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathol 19:357-364, 2009
19. Janzer RC, Burger PC, Giangaspero F, Paulus W: Craniopharyngioma. In: Kleihues P, Cavenee WK (eds) World Health Organization classification of tumours of the central nervous system. IARC, Lyon, 2000:244-246
20. Karavitaki N, Cudlip S, Adams C, Wass JAH: Craniopharyngiomas. Endocr Rev 27: 371-397, 2006
21. Karavitaki N, Wass JAH: Craniopharyngiomas. Endocrinol Metab Clin N Am 37: 173-193, 2008
22. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z: Localization of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study. Endocr Pathol 7: 63-70, 1996
23. Lee CH, Hung HW, Hung PH, Shieh YS: Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Mol Cancer 9:64, 2010
24. Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J: Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127: 841-844, 2011
25. Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M: Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol 16(6):718-721, 2011
26. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837- 1851, 2000
27. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S: Amplification of c-erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. Cancer 104: 1391-1397, 2005
28. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S: Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 68: 6377-6386, 2008
29. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002
30. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology; College of American Pathologists, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007
31. Zada G, Laws ER: Surgical management of craniopharyngiomas in the pediatric population. Horm Res Paediatr 74: 62-66, 2010
32. Zuhur SS, Musluman AM, Tanik C, Karaman O, Ozturk FY, Ozderya A, Ozkayalar H, Aydin Y, Altuntas Y: MGMT immunoexpression in adamantinomatous craniopharyngiomas. Pituitary 14: 323-327, 2011